Scleroderma, Systemic: Clinical Trials

9 trials for Scleroderma, Systemic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 unknown. 9 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Unknown 9
Phase 24Unknown 4

Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma
ADRCs, Standard Care, Placebo - Scleroderma, Diffuse
Phase 3UnknownParacrine, INC.1742023-02-282022-09-28
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
COVID-19 vaccine - Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
Phase 2 / Phase 3UnknownPaul R Fortin2872022-03-092023-01-17
Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis
Pirfenidone, Placebo oral capsule, Steroids - Systemic Sclerosis
Phase 2 / Phase 3UnknownRenJi Hospital722017-05-012017-03-01
Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis
Probiotic, Placebo - Systemic Sclerosis, Scleroderma
Phase 3UnknownFederal University of São Paulo762014-12-012014-11-27
Serial Night Time Position Splint on Systemic Sclerosis
Serial night time position splint, Drug treatment - Diffuse Systemic Sclerosis
Phase 3UnknownFederal University of São Paulo762010-01-012012-05-01
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
0.9% nitroglycerin in TAM cream, vehicle cream - Raynaud Disease
Phase 3UnknownMediQuest Therapeutics1002009-06-012010-07-20
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
Nitroglycerin, Topical AmphiMatrix - Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Phase 3UnknownMediQuest Therapeutics2002007-12-012010-02-05
Platelet Gel in Systemic Sclerosis
Platelet Gel - Scleroderma, Systemic
Phase 2 / Phase 3UnknownUniversità Politecnica delle Marche402007-03-012007-04-20
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
N-acetylcysteine (NAC) - Scleroderma, Diffuse
Phase 2 / Phase 3UnknownUniversità Politecnica delle Marche452007-01-012007-01-30

Narrower conditions

Scleroderma, Diffuse (7)  ·  Raynaud Disease (2)  ·  Arthritis, Rheumatoid (1)  ·  Lupus Erythematosus, Systemic (1)  ·  MASS syndrome (1)  ·  Systemic Vasculitis (1)  ·  Undifferentiated Connective Tissue Diseases (1)

Broader conditions

Connective Tissue Diseases (9)  ·  Skin Diseases (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Cardiovascular Diseases (3)  ·  Vascular Diseases (3)  ·  Embolism and Thrombosis (2)  ·  Livedoid Vasculopathy (2)  ·  Peripheral Vascular Diseases (2)  ·  Skin Diseases, Vascular (2)  ·  Thrombosis (2)  ·  Arthritis (1)  ·  Autoimmune Diseases (1)  ·  Immune System Diseases (1)  ·  Joint Diseases (1)

Interventions

Nitroglycerin (2)  ·  Acetylcysteine (1)  ·  COVID-19 Vaccines (1)  ·  Probiotics (1)  ·  Standard of Care (1)  ·  Steroids (1)  ·  pirfenidone (1)

Sponsors

Federal University of São Paulo (2)  ·  MediQuest Therapeutics (2)  ·  Università Politecnica delle Marche (2)  ·  Paracrine, INC. (1)  ·  Paul R Fortin (1)  ·  RenJi Hospital (1)

Countries

Brazil (2)  ·  Italy (2)  ·  United States (2)  ·  Canada (1)  ·  China (1)

Top investigators

Armando Gabrielli, MD, professor (1)  ·  Armando Gabrielli, MD,professor (1)  ·  Cristiane Kayser (1)  ·  Jamil Natour, PhD (1)  ·  Jan Ohrstrom, PhD (1)  ·  Jeff Gregory, MD (1)  ·  Paul R Fortin, MD,MPH,FRCPC (1)

Results publications

PMID 31056685